SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
KAI Pharmaceuticals, Inc. Announces Initiation of Phase 1b Study of KAI-4169 for the Treatment of Secondary Hyperparathyroidism (SHPT)